Development and Translation of Medical Technologies that Reduce Health Disparities (SBIR [R43/R44])
The summary for the Development and Translation of Medical Technologies that Reduce Health Disparities (SBIR [R43/R44]) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Development and Translation of Medical Technologies that Reduce Health Disparities (SBIR [R43/R44]): Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving a health disparity population. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 7-12 projects awarded as a result of this announcement is $3.45 million for fiscal year 2011. Future year amounts will depend on annual appropriations.
Federal Grant Title: | Development and Translation of Medical Technologies that Reduce Health Disparities (SBIR [R43/R44]) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-EB-10-002 |
Type of Funding: | Grant |
CFDA Numbers: | 93.242 |
CFDA Descriptions: | Mental Health Research Grants |
Current Application Deadline: | Jan 07, 2011 |
Original Application Deadline: | Jan 07, 2011 |
Posted Date: | Mar 19, 2010 |
Creation Date: | Mar 19, 2010 |
Archive Date: | Feb 07, 2011 |
Total Program Funding: | $3,450,000 |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...
- • Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional...
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
- • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
- • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
- More Grants from the National Institutes of Health
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...